Initiate Phase I/II clinical trials for mTLE, Fabry disease, and SOD1-ALS
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Feb 2024
- Due
- 30 Jun 2024
- Delivered
- August 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiation of Phase I/II clinical trials in mesial temporal lobe epilepsy (mTLE) and Fabry disease, in addition to SOD1-ALS, are expected in the first half of 2024”
What we found
Evidence strength A What the grades mean
The company did not initiate the trials by the first half of 2024; the first patient for the Fabry disease trial was dosed in August 2024, missing the deadline.
-
A uniQure N.V. 10-Q filed 2024-08-01
“We are also advancing three other product candidates into clinical development – AMT-260 for the treatment of refractory mesial temporal lobe epilepsy, AMT-162 for the treatment of SOD1-ALS and AMT-191 for the treatment of Fabry disease.” ✓ confirmed on the page
-
A uniQure N.V. 10-K filed 2025-02-27
“In August 2024, we announced that the first patient had been dosed in a Phase I/IIa clinical trial of AMT-191 for the treatment of Fabry disease.” ✓ confirmed on the page
Market reaction: the shares moved -4.8% against the S&P 500 over the three sessions around the disclosure (26 Feb 2025 to 3 Mar 2025). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase I/II clinical trials
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-QURE-001861 · Corrections policy